Lipoprotein (a) - A mysterious wheel of atherogenesis;Lipoprotein (a) - Misteriozni kotačić aterogeneze

Lijecnicki Vjesnik

Volumn 124, Issue 11-12, 2002, Pages 366-371

  Jelaković, Bojan ^a   Laganović, Mario ^a   Kuzmanić, Dusko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

Arteriosclerosis etiology; Lipoprotein (a) blood; Physiopathology

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A; APOLIPOPROTEIN B; ELASTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA; VITAMIN B COMPLEX;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG EFFICACY; DYSLIPIDEMIA; FAMILY HISTORY; FIBRINOLYSIS; FOAM CELL; GENETIC PREDISPOSITION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MACROPHAGE; NONHUMAN; OXIDATION; PATIENT SELECTION; PROGNOSIS; PROTEIN BINDING; RESTENOSIS; REVIEW; RISK FACTOR; THROMBOSIS; TISSUE REGENERATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ARTERIOSCLEROSIS; BLOOD; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ARTERIOSCLEROSIS; HUMANS; LIPOPROTEIN(A); RISK FACTORS;

EID: 0036942488     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Van den Hoogen PCW, Feskens EJM, Naglekerke NJD. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
2. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol 1989;64:555-9.
3. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H i dr. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project. 2000;355:675-87.
4. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo A. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease and renal disease. Am J Kid Dis 1999;33:225-34.
5. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann of Intern Med 1993;118:956-63.
6. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risk of cardiovascular disease. Causal or casual? Arch Intern Med 2000;160:422-34.
7. Von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein (a) further increases the fisk of coronary events in men with high global cardiovascular risk. J of Am Coll Cardiol 2001;37:434-9.
8. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082-5.
9. Kraft HG, Koechl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Gen 1992;90:220-30.
10. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene acounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992;90:52-60.
11. Kostner GM, Wo X, Frank S, Zimmermann R, Steyrer E. Metabolism of lipoprotein (a): assembly and excretion. Clin Genet 1997;52:347-54.
12. Sechi L, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E. Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with target organ damage in arterial hypertension. J Am Med Assoc 1997;277:1689-95.
13. Kronenberg F, Utermann, Dieplinger H. Lipoprotein (a) in renal disease. Am J Kid Dis 1996;27:1-25.
14. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing lp (a) levels. Circulation, 1989;80:1313-9.
15. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann. Lipoprotein (a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vase Biol 2000;20:522-8.
16. Welty FK, Lichtenstein AH, Barrett HR, Jenner JL, Dolnikowski GG, Schaefer EJ. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans. Arterioscler Throms Vasc Biol 2000;20:1807-10.
17. Wilson P, Myeres R, Larson M, Ordovas J, Wolf P, Schaefer E. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. J Am Med Assoc 1994;272:1666-71.
18. De Knijff P, Kaptein A, Boomsma D, Proncen HMG, Frants RR, Havekes L. Apoliprotein E polymorphism affects plasma levels of lipoprotein (a). Atherosclerosis 1991;90:59-65.
19. Jelaković B, Laganović M, Kuzmanić D, Sertić J, Ronćević T, Boršo G, Belev B, Željković T, Čvorišćec D, Stavljienić-Rukavina A. Polimorfizam Apo E gena, a ne ACE gena determinira vrijednosti arterijskog tlaka u ranoj fazi esencijalne hipertenzije?! Liječ Vjesn 2001;123(S2):82.
20. Cobb MM, Teitlebaum H, Risch N, Jekel J, Ostfeld A. Influence of dietary fat, apolipoprotein E phenotype and sex on plasma lipoprotein levels. Circulation 1992;86:849-57.
21. Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effects of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolemia. J Intern Med 1991;230:397-405.
22. Hoefler G, Harncourt F, Pashke E, Mirtl W, Pfeiffer KH, Kostner GM. Lipoprotein (a): a risk factor for myocardial infarction. Arteriosclerosis. 1988;8:398-401.
23. Rodengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in general population sample of middle aged men. Br Med J 1990;301:1248-51.
24. Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins L, Lewis C, Howard B, Savage P. Lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in Caucasians and African Americans. Arterioscler Thromb. 1993;13:1037-45.
25. Djurovic S, Berg K. Epidemiology of lp (a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997;52:281-92.
26. Mooser V, Berger M, Tappy L, Cayeux Ch, Marcovina S, Darioli R, Nicod P, Chiolero R. Reduction in plasma lp (a) levels during sepsis and bums. Arterioscler Thromb Vasc Biol 2000;20:1137-42.
27. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991;37:1950-4.
28. The Writing group for the PEPI Trial. Effects of estrogen on estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Assoc 1995;273:199-208.
29. Shlipak G, Somin JA, Vittinghoff E. Estrogen and progestin, lipoprotein (a) and the risk of recurrent coronary heart disease after menopause. J Am Med Assoc 2000;283:1845-52.
30. Hoff HF, Beck GJ, Skibinzski CI, Jurgens G, O'Neil JA, Kraft J, Lytle B. Serum lp (a) as predictor of vein stenosis after coronary artery bypass surgery. Circulation 1988;77:1238-44.
31. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apo B in human atherosclerotic lesions. J Lipid Res 1991;32:317-27.
32. Papagrikorakis E, Iliopoulos D, Asimacopoulos PJ, Safi HJ, Weilbaecher DJ, Ghazzaly KG, Nava ML, Gaubatz JW, Morrisett JD. Lipoprotein (a) in plasma, arterial wall and thrombus from patients with aortic aneurysm. Clin Genet 1997;52:262-71.
33. Scanu AM, Lawn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann of Intem Med 1991;115:209-18.
34. Boonmark NW, Lawn RM. The lysine-binding function of lp (a). Clin Genet 1997;52:355-60.
35. Poon M, Zhang X, Dunsky K, Taubman MB, Harpel PC. Apolipoprotein (a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet 1997;52:308-13.
36. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor β is severly depressed in advanced atherosclerosis. Int Med 1995;1:74-9.
37. GM, Grillhofer HK. Lipoprotein (a) mediates high affinity low density lipoprotein association to receptor negative fibroblasts. J Biol Chem 1991;266:21287-92.
38. Beige KE, Djurovic C, Muller HJ, Alestrom P, Berg K. Studies on effetcs of lp (a) on gene expression in endothelial cells in vitro. Clin Genet 1997;52:314-25.
39. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-92.
40. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after ballon coronary angioplasty. Circulation. 1995;91:1403-9.
41. Brown S, Morrisett J, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein (a) concentrations and apolipoprotein (a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk Communities (ARIC) Study. Atheroscler Thromb 1993;13:558-66.
42. Jauhianen M, Koskinen P, Ehnholm C i dr. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of Helsinki heart study participants. Atherosclerosis. 1991;89:59-67.
43. Alfthan G, Pekkanen J, Jauhianen M i dr. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in Finnish population based study. Atherosclerosis. 1994;106:9-19.
44. Ridker PM, Hennekens ChH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. J Am Med Assoc 1993;270:2195-9.
45. Cantin B, Gagon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais G. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study. J Am Cardiol Coll 1998;31:519-25.
46. Haffner SM, Moss SE, Klein BE i dr. Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin epidemiologic study of diabetic retinopathy. Metabolism 1992;41:194-7.
47. Wilson P, Myers R, Larson M, Ordovas J, Wolf P, Schaefer E. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. J Am Med Assoc 1994;272:1666-71.
48. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle men. Br Med J 1990;301:1248-51.
49. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J of Cardiol 1992;69:1251-4.
50. Cremer P, Nagel D, Labort B, Mann H, Muche R, Elster H, Siedel D. Lipoprotein (a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRISP). Eur J Clin Invest 1994;24:444-53.
51. Jones A, Lip G. Lipoprotein (a): more than just a bystander in the pathophysiology of hypertension? J Hum Hypert 1998;12:75-7.
52. Lip H, Jones A. Lipoprotein (a) and vascular disease: thrombogenesis and athreogenesis. Q J Med 1995;88:529-39.
53. Assman G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle - aged men. Am J Cardiol 1996;77:1179-84.
54. Dahlen G, Stenlund H. Lipoprotein (a) is a major risk factor for cardiovascular disease: pathogenic mechanism and clinical significance. Clin Genet 1997;52:272-80.
55. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi SI, Arakawa M. Localization of apolipoprotein (a) and apo B-100 in various renal diseases. Kidney Int. 1993;43:430-5.
56. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein (a): a dose-response study of the effects of cholestyramine in hypercholesterolemia. Atherosclerosis. 1982;44:61-71.
57. Thiery J, Armstrong VW, Schleef J, Creuztfeldt C, Creitzfeld W, Seidel D. Serum lipoprotein lp (a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 1988;66:462-3.
58. Berg K, Dahlen G, Chrisopherson B, Cook T, Ksekshus J, Pedersen T. Lp (a) level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52:254-61.
59. Gurakar A, Hoeg J, Kostner G, Papadopoulos N, Brewer Jr H. Levels of lipoprotein (a) decline with neomycin and niacin treatment. Atherosclerosis 1985;57:293.
60. Foody JM, Milberg J, Robinson K, Pearce G, Jacobsen D, Sprecher D. Homocysteine an lipoprotein (a) interact to increase CAD risk in woung men and women. Arterioscler Thromb Vasc Biol 2000;20:493-9.